

# Dermatology Referral Form



Fax Completed Form To:

Phone:

| PATIENT INFORMATION         |                 |                |   |
|-----------------------------|-----------------|----------------|---|
| Patient Name:               | Date of Birth:  | Referral Date: |   |
| Address:                    | City/State/Zip: |                |   |
| Home Phone:                 | Cell Phone:     | Work Phone:    |   |
| Secondary Contact:          | Height:         | Weight:        | <input type="checkbox"/> Male <input type="checkbox"/> Female |
| Patient Diagnosis & ICD-10: |                 |                |   |
| Allergies:                  |                 |                |   |

| PROVIDER INFORMATION                   |                 |        |  |
|--|-----------------|--------|--|
| Physician Name:                        | Lic.#:          | DEA #: |  |
| Practice Name:                         | NPI#:           |        |  |
| Address:                               | City/State/Zip: |        |  |
| Office Contact:                        | Phone:          | Fax:   |  |
| Supervisory Physician (if applicable): |                 |        |  |

| PLEASE ATTACH   |   |
|---|---|
| <input type="checkbox"/> Patient demographics & front/back copy of all insurance cards (prescription & medical) | <input type="checkbox"/> TB lab results within last 12 months ( <i>Stelara, Simponi Aria, Ilumya &amp; Infliximabs only</i> ) |
| <input type="checkbox"/> Recent office visit notes, history & physical, lab & pertinent procedure results       | <input type="checkbox"/> HBV lab results within last 12 months ( <i>Infliximabs &amp; Simponi Aria only</i> )                 |
| <input type="checkbox"/> Current medication list & list of prior medications tried and failed (with dates)      | <input type="checkbox"/> Letter of medical necessity if drug dosing or indication is outside of FDA guidelines                |

| NURSING & LAB ORDERS   |  |
|--|--|
| <b>Nurse Orders:</b> Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.  |  |
| <b>Flush Orders:</b> NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - <input type="checkbox"/> 10units/mL ---OR--- <input type="checkbox"/> 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line |  |
| <b>Lab Orders:</b> <b>Lab Date &amp; Frequency:</b>  |  |

| PRESCRIPTION ORDERS   |   |  |  |
|---|---|--|--|
| <b>Anaphylaxis Kit:</b>   | <input type="checkbox"/> Epinephrine 0.3mg IM as needed   | <input type="checkbox"/> Solu-cortef 250mg-500mg IV as needed                    | <input type="checkbox"/> Solu-Medrol 60mg - 125mg IV as needed |
| (Check all that apply)  | <input type="checkbox"/> Diphenhydramine _____ mg IV as needed  | <input type="checkbox"/> NS Hydration 500 ml IV over 30 minutes as needed        | <input type="checkbox"/> Other _____                           |
| <b>Pre-Medications:</b>   | <input type="checkbox"/> Acetaminophen _____ mg PO _____ minutes prior to infusion  | <input type="checkbox"/> Solu-Medrol _____ mg IV _____ minutes prior to infusion |  |
| (Check all that apply)  | <input type="checkbox"/> Diphenhydramine _____ mg <input type="checkbox"/> PO ---OR--- <input type="checkbox"/> IV infusion _____ minutes prior to infusion | <input type="checkbox"/> Other _____   |  |
| <b>Supply Orders:</b> All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary |   |  |  |

| PRODUCT   | PRESCRIPTION INFORMATION   | REFILLS |
|---|--|---------|
| Is this a first dose? <input type="checkbox"/> Yes <input type="checkbox"/> No If No, when was last dose given? _____ When is patient due for next dose? _____                          |  |         |
| <input type="checkbox"/> ILUMYA   | 100mg SC injection at 0 and 4 weeks then every 12 weeks  | _____   |
| <input type="checkbox"/> INFlixIMAB<br><input type="checkbox"/> Avsola<br><input type="checkbox"/> Inflectra<br><input type="checkbox"/> Remicade<br><input type="checkbox"/> Renflexis | <input type="checkbox"/> <b>Induction:</b> _____ mg/kg or _____ mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over at least 2 hours at weeks 0, 2, and 6  | NONE    |
|   | <input type="checkbox"/> <b>Maintenance:</b> _____ mg/kg _____ mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over at least 2 hours every _____ weeks<br><i>(Note: Round to nearest 100mg for Medicaid patients)</i><br>If Remicade infusion tolerated, adjust infusion time according to manufacturer package insert.   | _____   |
| <input type="checkbox"/> SIMPONI ARIA   | 2 mg/kg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter   | _____   |
| <input type="checkbox"/> SPEVIGO  | <input type="checkbox"/> 900 mg IV infusion over 90 minutes <input type="checkbox"/> Additional 900 mg IV infusion over 90 minutes one week after initial dose if flare symptoms persist   | _____   |
| <input type="checkbox"/> STELARA  | <b>Psoriasis Adult Subcutaneous</b><br><input type="checkbox"/> For patients <= 100 kg, 45 mg SC injection initially and 4 weeks later, followed by 45 mg every 12 weeks<br><input type="checkbox"/> For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks   | _____   |
|   | <b>Psoriasis Pediatric Patients 6 to 17 (based on weight at time of initial dose)</b><br><input type="checkbox"/> For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks<br><input type="checkbox"/> For patients 60 kg – 100kg, 45 mg SC injection initially and 4 weeks later, then every 12 weeks<br><input type="checkbox"/> For patients >100kg, 90 mg SC injection initially and 4 weeks later, then every 12 weeks | _____   |
|   | <b>Psoriatic Arthritis Adult</b><br><input type="checkbox"/> 45 mg SC injection initially and 4 weeks later, followed by 45 mg SC injection every 12 weeks<br><input type="checkbox"/> For patients with co-existent moderate-to-severe plaque psoriasis weighing >100 kg, 90 mg SC injection initially and 4 weeks later, then every 12 weeks   | _____   |
| <input type="checkbox"/> XOLAIR   | <input type="checkbox"/> 150 or <input type="checkbox"/> 300 mg SC injection once every 4 weeks  | _____   |
| <input type="checkbox"/> IG   | <b>For Immunoglobulin therapy please refer to Immunoglobulin Form</b>  | _____   |
| <input type="checkbox"/> OTHER  |  | _____   |

*By signing this form and utilizing our services, you are authorizing Amerita to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.*

Prescriber's Signature \_\_\_\_\_  
Dispense as Written

Print Name \_\_\_\_\_ Date \_\_\_\_\_

Prescriber's Signature \_\_\_\_\_  
Substitution Permitted

Print Name \_\_\_\_\_ Date \_\_\_\_\_

